Genetic causes of primary aldosteronism

다국어 초록 (Multilingual Abstract)

Primary aldosteronism is characterized by at least partially autonomous production of the adrenal steroid hormone aldosterone and is the most common cause of secondary hypertension. The most frequent subforms are idiopathic hyperaldosteronism and aldosterone-producing adenoma. Rare causes include unilateral hyperplasia, adrenocortical carcinoma and Mendelian forms (familial hyperaldosteronism). Studies conducted in the last eight years have identified somatic driver mutations in a substantial portion of aldosterone-producing adenomas, including the genes KCNJ5 (encoding inwardly rectifying potassium channel GIRK4), CACNA1D (encoding a subunit of L-type voltage-gated calcium channel CaV1.3), ATP1A1 (encoding a subunit of Na+/K+-ATPase), ATP2B3 (encoding a Ca2+-ATPase), and CTNNB1 (encoding ß-catenin). In addition, aldosterone-producing cells were recently reported to form small clusters (aldosterone-producing cell clusters) beneath the adrenal capsule. Such clusters accumulate with age and appear to be more frequent in individuals with idiopathic hyperaldosteronism. The fact that they are associated with somatic mutations implicated in aldosterone-producing adenomas also suggests a precursor function for adenomas. Rare germline variants of CYP11B2 (encoding aldosterone synthase), CLCN2 (encoding voltage-gated chloride channel ClC2), KCNJ5, CACNA1H (encoding a subunit of T-type voltage-gated calcium channel CaV3.2), and CACNA1D have been reported in different subtypes of familial hyperaldosteronism. Collectively, these studies suggest that primary aldosteronism is largely due to genetic mutations in single genes, with potential implications for diagnosis and therapy.

참고문헌 (Reference)

• 1 Juhlin, C. C., "Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma" 100 : E493-E502, 2015
• 2 Jung, J., "Variations in the potassium channel genes KCNK3 and KCNK9 in relation to blood pressure and aldosterone production : an exploratory study" 97 : E2160-E2167, 2012
• 3 Wu, V. C., "The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes" 7 : 39121-, 2017
• 4 Funder, J. W., "The management of primary aldosteronism : case detection, diagnosis, and treatment : an Endocrine Society Clinical Practice Guideline" 101 : 1889-1916, 2016
• 5 Penton, D., "Task3 potassium channel gene invalidation causes low renin and salt-sensitive arterial hypertension" 153 : 4740-4748, 2012
• 6 Nanba, K., "Targeted molecular characterization of aldosterone-producing adenomas in White Americans" 103 : 3869-3876, 2018
• 7 Hardege, I., "Targeted disruption of the Kcnj5 gene in the female mouse lowers aldosterone levels" 132 : 145-156, 2018
• 8 Guagliardo, N. A., "TASK-3 channel deletion in mice recapitulates low-renin essential hypertension" 59 : 999-1005, 2012
• 9 Davies, L. A., "TASK channel deletion in mice causes primary hyperaldosteronism" 105 : 2203-2208, 2008
• 10 O’Roak, B. J., "Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations" 485 : 246-250, 2012
• 11 Williams, B., "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension(PATHWAY2) : a randomised, double-blind, crossover trial" 386 : 2059-2068, 2015
• 12 Azizan, E. A., "Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension" 45 : 1055-1060, 2013
• 13 Beuschlein, F., "Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension" 45 : 440-444, 2013
• 14 Scholl, U. I., "Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism" 45 : 1050-1054, 2013
• 15 Tamura, A., "Somatic KCNJ5 mutation occurring early in adrenal development may cause a novel form of juvenile primary aldosteronism" 441 : 134-139, 2017
• 16 Williams, T. A., "Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas" 63 : 188-195, 2014
• 17 Gu, H., "Salt-dependent Blood Pressure in Human Aldosterone SynthaseTransgenic Mice" 7 : 492-, 2017
• 18 Scholl, U. I., "Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism" 4 : e06315-, 2015
• 19 Goh, G., "Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors" 46 : 613-, 2014
• 20 Young, W. F., "Primary aldosteronism : renaissance of a syndrome" 66 : 607-618, 2007
• 21 Boulkroun, S., "Prevalence, clinical, and molecular correlates of KCNJ5mutations in primary aldosteronism" 59 : 592-598, 2012
• 22 Ohno, Y., "Prevalence of cardiovascular disease and its risk factors in primary aldosteronism : a multicenter study in Japan" 71 : 530-537, 2018
• 23 Monticone, S., "Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice" 69 : 1811-1820, 2017
• 24 Wu, V. C., "Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population" 5 : 11396-, 2015
• 25 Mulatero, P., "Prevalence and characteristics of familial hyperaldosteronism" 58 : 797-803, 2011
• 26 Conn, J. W., "Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome" 45 : 3-17, 1955
• 27 Murtha, T. D., "Pregnancy, primary aldosteronism, and somatic CTNNB1 mutations" 374 : 1492-1494, 2016
• 28 Teo, A. E. D., "Pregnancy, primary aldosteronism, and adrenal CTNNB1mutations" 373 : 1429-1436, 2015
• 29 Chen, A. X., "Potassium channels related to primary aldosteronism : expression similarities and differences between human and rat adrenals" 417 : 141-148, 2015
• 30 Williams, T. A., "Outcomes after adrenalectomy for unilateral primary aldosteronism : an international consensus on outcome measures and analysis of remission rates in an international cohort" 5 : 689-699, 2017
• 31 Scholl, U. I., "Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype" 83 : 779-789, 2015
• 32 Pinggera, A., "New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy" 26 : 2923-2932, 2017
• 33 Tissier, F., "Mutations of β-catenin in adrenocortical tumors : activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors" 65 : 7622-7627, 2005
• 34 Nanba, K., "Molecular heterogeneity in aldosterone-producing adenomas" 101 : 999-1007, 2016
• 35 Bichet, D., "Merging functional studies with structures of inward-rectifier K(+)channels" 4 : 957-967, 2003
• 36 Scholl, U. I., "Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma" 127 : 2739-2750, 2017
• 37 Maiolino, G., "Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism" 27 : 200-205, 2018
• 38 Manichaikul, A., "KCNK3 variants are associated with hyperaldosteronism and hypertension" 68 : 356-364, 2016
• 39 Mulatero, P., "KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism" 59 : 235-240, 2012
• 40 Choi, M., "K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension" 331 : 768-772, 2011
• 41 Farge, D., "Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma" 83 : 635-640, 1987
• 42 Heitzmann, D., "Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis" 27 : 179-187, 2008
• 43 Catterall, W. A., "International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels" 55 : 579-581, 2003
• 44 Murakami, M., "Integration of transcriptome and methylome analysis of aldosterone-producing adenomas" 173 : 185-195, 2015
• 45 Howard, B., "Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas" 99 : E536-E543, 2014
• 46 Yoshii, Y., "Hypomethylation of CYP11B2 in aldosterone-producing adenoma" 68 : 1432-1437, 2016
• 47 Sutherland, D. J., "Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone" 95 : 1109-1119, 1966
• 48 Scholl, U. I., "Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5" 109 : 2533-2538, 2012
• 49 Nanba, K., "Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry" 98 : 1567-1574, 2013
• 50 Lifton, R. P., "Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase" 2 : 66-74, 1992
• 51 Williams, T. A., "Genotype-specific steroid profiles associated with aldosterone-producing adenomas" 67 : 139-145, 2016
• 52 Lerario, A. M., "Genetics of aldosterone-producing adenomas with pathogenic KCNJ5 variants" 26 : 463-470, 2019
• 53 Hong, A. R., "Genetics of aldosterone-producing adenoma in Korean patients" 11 : e0147590-, 2016
• 54 Fernandes-Rosa, F. L., "Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma" 64 : 354-361, 2014
• 55 Perez-Rivas, L. G., "Genetic characterization of a mouse line with primary aldosteronism" 58 : 67-78, 2017
• 56 Nanba, K., "Genetic characteristics of aldosterone-producing adenomas in Blacks" 73 : 885-892, 2019
• 57 Zennaro, M. C., "Genetic causes of functional adrenocortical adenomas" 38 : 516-537, 2017
• 58 Tadjine, M., "Frequent mutations of betacatenin gene in sporadic secreting adrenocortical adenomas" 68 : 264-270, 2008
• 59 Taguchi, R., "Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas" 97 : 1311-1319, 2012
• 60 Milliez, P., "Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism" 45 : 1243-1248, 2005
• 61 Stowasser, M., "Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I" 90 : 5070-5076, 2005
• 62 Lichtenauer, U., "Establishment of an in vivo model for KCNJ5 dependent hyperaldosteronism" 123 : P09_25-, 2015
• 63 Spyroglou, A., "Diastrophic dysplasia sulfate transporter(SLC26A2)is expressed in the adrenal cortex and regulates aldosterone secretion" 63 : 1102-1109, 2014
• 64 Iossifov, I., "De novo gene disruptions in children on the autistic spectrum" 74 : 285-299, 2012
• 65 Spat, A., "Control of aldosterone secretion : a model for convergence in cellular signaling pathways" 84 : 489-539, 2004
• 66 Berthon, A., "Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development" 19 : 1561-1576, 2010
• 67 Akerstrom, T., "Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter" 7 : e41926-, 2012
• 68 Gordon, R. D., "Clinical and pathological diversity of primary aldosteronism, including a new familial variety" 18 : 283-286, 1991
• 69 Nugrahaningsih, D. A. A., "Chronic hyperaldosteronism in Cryptochromenull mice induces high-salt-and blood pressure-independent kidney damage in mice" 37 : 202-209, 2014
• 70 Tauber, P., "Cellular pathophysiology of an adrenal adenoma-associated mutant of the plasma membrane Ca-ATPase ATP2B3" 157 : 2489-2499, 2016
• 71 Omata, K., "Cellular and genetic causes of idiopathic hyperaldosteronism" 72 : 874-880, 2018
• 72 Monticone, S., "Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension : a systematic review and meta-analysis" 6 : 41-50, 2018
• 73 Hundemer, G. L., "Cardiometabolic outcomes and mortality in medically treated primary aldosteronism : a retrospective cohort study" 6 : 51-59, 2018
• 74 Scholl, U. I., "CLCN2 chloride channel mutations in familial hyperaldosteronism type II" 50 : 349-354, 2018
• 75 Reimer, E. N., "CACNA1HM1549VMutant calcium channel causes autonomous aldosterone production in HAC15 cells and is inhibited by mibefradil" 157 : 3016-3022, 2016
• 76 Daniil, G., "CACNA1H mutations are associated with different forms of primary aldosteronism" 13 : 225-236, 2016
• 77 Imrie, H., "Association between aldosterone production and variation in the 11beta-hydroxylase(CYP11B1)gene" 91 : 5051-5056, 2006
• 78 Korah, H. E., "An update on familial hyperaldosteronism" 47 : 941-946, 2015
• 79 Masilamani, S., "Aldosteronemediated regulation of ENaC α, β, and γ subunit proteins in rat kidney" 104 : R19-R23, 1999
• 80 Nishimoto, K., "Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands" 112 : E4591-E4599, 2015
• 81 Seccia, T. M., "Aldosterone-producing adrenocortical carcinoma : an unusual cause of Conn’s syndrome with an ominous clinical course" 12 : 149-159, 2005
• 82 Vouillarmet, J., "Aldosterone-producing adenoma with a somatic KCNJ5mutation revealing APC-dependent familial adenomatous polyposis" 101 : 3874-3878, 2016
• 83 Nishimoto, K., "Adrenocortical zonation in humans under normal and pathological conditions" 95 : 2296-2305, 2010
• 84 Fassnacht, M., "Adrenocortical carcinoma : a clinician’s update" 7 : 323-335, 2011
• 85 Guagliardo, N. A., "Adrenal tissue-specific deletion of TASK channels causes aldosterone-driven angiotensin II–independent hypertension" 73 : 407-414, 2019
• 86 Dekkers, T., "Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?" 99 : E1341-E1351, 2014
• 87 Akerstrom, T., "Activating mutations in CTNNB1 in aldosterone producing adenomas" 6 : 19546-, 2016
• 88 Gekle, M., "Actions of aldosterone in the cardiovascular system:the good, the bad, and the ugly?" 458 : 231-246, 2009
• 89 Rossi, G. P., "A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients" 48 : 2293-2300, 2006
• 90 Lafferty, A. R., "A novel genetic locus for low renin hypertension : familial hyperaldosteronism type II maps to chromosome 7(7p22)" 37 : 831-835, 2000
• 91 Geller, D. S., "A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism" 93 : 3117-3123, 2008
• 92 Monticone, S., "A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III" 98 : E1861-E1865, 2013
• 93 Lenzini, L., "A meta-analysis of somatic KCNJ5 K(+)channel mutations In 1636 patients with an aldosterone-producing adenoma" 100 : E1089-E1095, 2015
• 94 Fernandes-Rosa, F. L., "A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism" 50 : 355-361, 2018
• 95 Heginbotham, L., "A functional connection between the pores of distantly related ion channels as revealed by mutant K+channels" 258 : 1152-1155, 1992
• 96 Lifton, R. P., "A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension" 355 : 262-265, 1992
• 97 Monticone, S., "A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue" 100 : E114-E118, 2015
• 98 Flanagan, S., "A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia" 18 : 320-323, 2017